Identifying Host Pathways Important to Protective Immunity Against CCHFV
Abstract
Currently, no CCHFV vaccine candidates have reached Phase I clinical trials curtailing the understanding of immunity build against CCHFV versus other VHFs. Many candidates for such a vaccine have proven to be either ineffective at conferring protection against CCHFV challenge or require multiple doses. Most of the those require multiple doses to infer protection also make use of other viral vector platforms other then CCHFV, which can skew immunological responses and prove problematic for vaccine development. The objective of this work will be to define the correlates of protection associated with immunity against a broadspectrum of CCHFV strains using a CCHFV viral replicon particle system (VRP). Additionally, the grantee will seek to identify other immunological pathways that can further enhance protection. This will to allow for future development of single dose vaccines and antibody-based therapeutics for use against CCHFV and other VHFs.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jun 14, 2022
- Source ID
- HDTRA12110005
Entities
People
- Scott D Pegan
Organizations
- Defense Threat Reduction Agency
- University of Georgia